SCHEMBL87305

SCHEMBL87305

CCCCOC(=O)NCC1CCc2nc(C(=O)OCC)c(O)c(=O)n2CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
ALDH1A1 P00352 4/20 0.41
TSHR P16473 4/20 0.41
RAB9A P51151 3/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.34
POLB P06746 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87301 0.89 MAPT (0.40) MAPTALDH1A1TSHRRAB9AALOX15
SCHEMBL87323 0.84 F2 (0.43) MAPTALDH1A1TSHRRAB9AALOX15
SCHEMBL13691707 0.82 KCNH2 (0.46) MAPTTSHRSMN1; SMN2NPSR1GAA
SCHEMBL87444 0.80 MAPT (0.48) MAPTALDH1A1TSHRRAB9AALOX15
SCHEMBL87293 0.71 TSHR (0.33) MAPTALDH1A1TSHRRAB9AALOX15
SCHEMBL2530132 0.69 MAPT (0.45) MAPTALDH1A1TSHRRAB9AALOX15
SCHEMBL87285 0.69 CYP1A2 (0.40) MAPTALDH1A1TSHRHSD17B10KDM4E
SCHEMBL16145641 0.69 ACHE (0.53)
SCHEMBL87894 0.68 TSHR (0.34) TSHRRAB9ASMN1; SMN2HPGDNPC1
SCHEMBL13691809 0.67 KCNH2 (0.45) MAPTALDH1A1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed